Occupational Asthma Reference

Inman MD, Watson R, Cockcroft DW, Wong BJ, Hargreave FE, O'Byrne PM, Reproducibility of allergen-induced early and late asthmatic responses, J Allergy Clin Immunol, 1995;95:1191-1195,

Keywords: reproducibility, FEV1, power, ch, methods

Known Authors

Freddy Hargreave, McMaster University, Hamilton Freddy Hargreave

Don Cockcroft, Saskatoon Don Cockcroft

If you would like to become a known author and have your picture displayed along with your papers then please get in touch from the contact page. Known authors can choose to receive emails when their papers receive comments.

Abstract

BACKGROUND: Constant-dose allergen inhalation challenges are frequently used to examine the effect of antiasthma drugs on the allergen-induced early and late asthmatic responses. The end- point measurements in such studies are the maximal early and late percent decreases in the forced expiratory volume in 1 second (FEV1).

OBJECTIVE: Our purpose was to observe the reproducibility and to determine the sample sizes required for such studies.

METHODS: Twenty-eight subjects with allergen-induced early and late responses were studied with two constant-dose allergen challenges separated by 2 to 12 weeks. The early response was measured as the maximum percent decrease in FEV1 during the first 2 hours and the late response as the maximum percent decrease in FEV1 between 3 to 7 hours.
RESULTS: The mean +/- SEM early responses were 23.1% +/- 1.0% and 24.7% +/- 2.0%, whereas the mean late responses were 23.3% +/- 2.0% and 24.5% +/-2.2%. Reproducibility of measurements were such that fewer than eight subjects are required, to show 50% attenuation of either the early or late response (with 90% power).

CONCLUSIONS: The method of constant-dose allergen challenge is a sensitive tool for detecting changes in early and late asthmatic responses after the use of antiasthma medication 0 (Allergens)

Full Text

Full text of this reference not available

Please Log In or Register to add the full text to this reference

Comments

Please sign in or register to add your thoughts.


Oasys and occupational asthma smoke logo